Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMIT MAHIPAL

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1417148180
CMS profile
1355380
Location
ROCHESTER, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$184,513.90

176 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $126,278.64 100
Exelixis Inc. $39,377.70 50
TAIHO ONCOLOGY, INC. $11,841.43 11
Merck Sharp & Dohme LLC $2,745.00 1
Eisai Inc. $2,347.16 4
AstraZeneca UK Limited $1,370.00 1
Incyte Corporation $264.55 5
Bayer Healthcare Pharmaceuticals Inc. $135.09 1
Genentech USA, Inc. $130.79 2
Seagen Inc. $23.54 1

Page 2 of 4; records 51–100 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMIT MAHIPAL

NPI 1417148180 · CMS profile ID 1355380

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

ROCHESTER, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417148180?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMIT MAHIPAL, NPI 1417148180, CMS profile ID 1355380. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417148180?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). AMIT MAHIPAL, NPI 1417148180, CMS profile ID 1355380. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417148180?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
AMIT MAHIPAL, NPI 1417148180, CMS profile ID 1355380, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1417148180?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

176 matching records · $184,513.90 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 176 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 176.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $16.3510/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016274415 CMS
AstraZeneca Pharmaceuticals LP $205.3110/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011364139 CMS
AstraZeneca Pharmaceuticals LP $10.0010/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015258297 CMS
AstraZeneca Pharmaceuticals LP $125.0010/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015289521 CMS
AstraZeneca Pharmaceuticals LP $196.5010/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015891589 CMS
AstraZeneca Pharmaceuticals LP $104.8910/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015819201 CMS
Genentech USA, Inc. $116.4710/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040293063 CMS
Exelixis Inc. $17.9410/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044605181 CMS
Exelixis Inc. $47.4510/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044605311 CMS
AstraZeneca Pharmaceuticals LP $1,350.0009/28/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014363313 CMS
Incyte Corporation $124.9909/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044476127 CMS
AstraZeneca Pharmaceuticals LP $5,500.0009/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014156607 CMS
Incyte Corporation $89.9509/22/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044476111 CMS
AstraZeneca Pharmaceuticals LP $600.0009/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011300165 CMS
Genentech USA, Inc. $14.3209/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040293069 CMS
AstraZeneca Pharmaceuticals LP $14.4509/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015048323 CMS
AstraZeneca Pharmaceuticals LP $135.0009/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014444035 CMS
AstraZeneca Pharmaceuticals LP $217.8009/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015611363 CMS
Eisai Inc. $20.0909/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023300975 CMS
Exelixis Inc. $4,290.0009/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044597915 CMS
Exelixis Inc. $763.0008/31/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044594357 CMS
Exelixis Inc. $125.0008/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044594369 CMS
Incyte Corporation $17.4608/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044476069 CMS
Bayer Healthcare Pharmaceuticals Inc. $135.0908/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000699387 CMS
AstraZeneca Pharmaceuticals LP $14.6008/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015620175 CMS
AstraZeneca Pharmaceuticals LP $85.9008/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015405547 CMS
Exelixis Inc. $1,980.0008/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044589911 CMS
Exelixis Inc. $1,980.0008/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044589959 CMS
AstraZeneca Pharmaceuticals LP $1,712.5007/22/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014360569 CMS
AstraZeneca Pharmaceuticals LP $4,100.0007/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015028395 CMS
AstraZeneca Pharmaceuticals LP $32.9207/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015121507 CMS
AstraZeneca Pharmaceuticals LP $4,100.0006/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016084683 CMS
AstraZeneca Pharmaceuticals LP $65.5006/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014929831 CMS
AstraZeneca Pharmaceuticals LP $37.9506/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016271299 CMS
AstraZeneca Pharmaceuticals LP $96.3906/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012050381 CMS
AstraZeneca Pharmaceuticals LP $2,750.0006/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011732057 CMS
AstraZeneca Pharmaceuticals LP $135.0006/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011824763 CMS
AstraZeneca Pharmaceuticals LP $19.9606/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015160117 CMS
Incyte Corporation $21.6606/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044476015 CMS
AstraZeneca Pharmaceuticals LP $72.5306/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011952941 CMS
AstraZeneca Pharmaceuticals LP $21.8106/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012017637 CMS
AstraZeneca Pharmaceuticals LP $5,500.0006/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016095011 CMS
Eisai Inc. $22.7705/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023300973 CMS
AstraZeneca Pharmaceuticals LP $135.0705/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011675321 CMS
AstraZeneca Pharmaceuticals LP $722.8005/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014315033 CMS
AstraZeneca Pharmaceuticals LP $60.4105/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015321587 CMS
AstraZeneca Pharmaceuticals LP $192.2605/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015747919 CMS
AstraZeneca Pharmaceuticals LP $12.7405/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015892803 CMS
AstraZeneca Pharmaceuticals LP $5,500.0005/19/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011466241 CMS
Merck Sharp & Dohme LLC $2,745.0005/15/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048406255 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $16,636.15 20
PY2020 $4,270.37 3
PY2021 $11,294.85 7
PY2022 $58,554.39 64
PY2023 $184,513.90 176
PY2024 $182,863.55 205
PY2025 $287,739.15 213

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $296.25 3
PY2025 Principal investigator $575,905.84 240
PY2024 Principal investigator $439,312.75 208
PY2023 Principal investigator $313,521.56 48
PY2022 Principal investigator $289,948.89 80
PY2021 Principal investigator $1,030,574.28 89
PY2020 Recipient $2,624.47 4
PY2020 Principal investigator $779,916.52 120
PY2019 Recipient $886.00 1
PY2019 Principal investigator $1,155,878.38 105

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

243 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $3,304.00 12/22/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426444
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,500.00 12/17/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination with Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma No dispute reported 06/30/2026 1215505521
Principal investigator 1 Alnylam Pharmaceuticals Inc. $210.00 12/17/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination with Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma No dispute reported 06/30/2026 1215505533
Principal investigator 1 Alnylam Pharmaceuticals Inc. $723.80 12/03/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination with Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma No dispute reported 06/30/2026 1215505524
Principal investigator 1 Alnylam Pharmaceuticals Inc. $483.00 12/01/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination with Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma No dispute reported 06/30/2026 1215505529
Principal investigator 1 ABBVIE INC. $3,304.00 11/27/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426410
Principal investigator 1 ABBVIE INC. $1,867.60 11/27/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426414
Principal investigator 1 ABBVIE INC. $1,867.60 11/27/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426418
Principal investigator 1 ABBVIE INC. $3,304.00 11/27/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426422
Principal investigator 1 Genentech, Inc. $1,400.00 11/13/2025 Non-covered Recipient Entity
UNIVERSITY HOSPITALS OF CLEVELAND
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211677619
Principal investigator 1 Genentech, Inc. $2,800.00 11/13/2025 Non-covered Recipient Entity
UNIVERSITY HOSPITALS OF CLEVELAND
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211677623
Principal investigator 1 Genentech, Inc. $1,050.00 11/13/2025 Non-covered Recipient Entity
UNIVERSITY HOSPITALS OF CLEVELAND
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211677627
Principal investigator 1 Genentech, Inc. $1,400.00 11/04/2025 Non-covered Recipient Entity
UNIVERSITY HOSPITALS OF CLEVELAND
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211677617
Principal investigator 1 Genentech, Inc. $700.00 11/04/2025 Non-covered Recipient Entity
UNIVERSITY HOSPITALS OF CLEVELAND
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211677621
Principal investigator 1 Genentech, Inc. $3,500.00 11/04/2025 Non-covered Recipient Entity
UNIVERSITY HOSPITALS OF CLEVELAND
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211677625
Principal investigator 1 ABBVIE INC. $3,809.40 10/27/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426333
Principal investigator 1 Genentech, Inc. $1,750.00 10/23/2025 Non-covered Recipient Entity
UNIVERSITY HOSPITALS OF CLEVELAND
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211677611
Principal investigator 1 Genentech, Inc. $1,400.00 10/07/2025 Non-covered Recipient Entity
UNIVERSITY HOSPITALS OF CLEVELAND
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211677613
Principal investigator 1 Genentech, Inc. $8,820.00 10/07/2025 Non-covered Recipient Entity
UNIVERSITY HOSPITALS OF CLEVELAND
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211677615
Principal investigator 1 ABBVIE INC. $3,304.00 09/29/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426185
Principal investigator 1 ABBVIE INC. $1,867.60 09/29/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426199
Principal investigator 1 ABBVIE INC. $112.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425875
Principal investigator 1 ABBVIE INC. $112.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425880
Principal investigator 1 ABBVIE INC. $60.20 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425884
Principal investigator 1 ABBVIE INC. $179.20 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425886
Principal investigator 1 ABBVIE INC. $401.80 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425889
Principal investigator 1 ABBVIE INC. $785.40 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425893
Principal investigator 1 ABBVIE INC. $2,590.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425897
Principal investigator 1 ABBVIE INC. $3,710.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425901
Principal investigator 1 ABBVIE INC. $5,531.40 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425906
Principal investigator 1 ABBVIE INC. $3,710.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425909
Principal investigator 1 ABBVIE INC. $196.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425913
Principal investigator 1 ABBVIE INC. $33.60 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425917
Principal investigator 1 ABBVIE INC. $2,590.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425921
Principal investigator 1 ABBVIE INC. $310.80 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425925
Principal investigator 1 ABBVIE INC. $112.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425928
Principal investigator 1 ABBVIE INC. $4,302.20 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425932
Principal investigator 1 ABBVIE INC. $49.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425936
Principal investigator 1 ABBVIE INC. $952.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425939
Principal investigator 1 ABBVIE INC. $2,590.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425944
Principal investigator 1 ABBVIE INC. $7,000.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425948
Principal investigator 1 ABBVIE INC. $112.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425952
Principal investigator 1 ABBVIE INC. $459.20 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425955
Principal investigator 1 ABBVIE INC. $3,710.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425960
Principal investigator 1 ABBVIE INC. $196.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425964
Principal investigator 1 ABBVIE INC. $3,710.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425968
Principal investigator 1 ABBVIE INC. $3,710.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425972
Principal investigator 1 ABBVIE INC. $64.40 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425976
Principal investigator 1 ABBVIE INC. $614.60 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425980
Principal investigator 1 ABBVIE INC. $1,071.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425984
Principal investigator 1 ABBVIE INC. $2,450.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425988
Principal investigator 1 ABBVIE INC. $401.80 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425992
Principal investigator 1 ABBVIE INC. $320.88 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425996
Principal investigator 1 ABBVIE INC. $310.80 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426000
Principal investigator 1 ABBVIE INC. $304.20 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426005
Principal investigator 1 ABBVIE INC. $112.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426008
Principal investigator 1 ABBVIE INC. $51.80 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426013
Principal investigator 1 ABBVIE INC. $2,590.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426017
Principal investigator 1 ABBVIE INC. $344.40 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426021
Principal investigator 1 ABBVIE INC. $3,710.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426025
Principal investigator 1 ABBVIE INC. $2,458.40 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426030
Principal investigator 1 ABBVIE INC. $4,302.20 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426035
Principal investigator 1 ABBVIE INC. $75.60 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426040
Principal investigator 1 ABBVIE INC. $2,590.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426044
Principal investigator 1 ABBVIE INC. $3,868.20 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426050
Principal investigator 1 ABBVIE INC. $112.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426054
Principal investigator 1 ABBVIE INC. $3,073.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426057
Principal investigator 1 ABBVIE INC. $4,244.80 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426062
Principal investigator 1 ABBVIE INC. $4,244.80 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426065
Principal investigator 1 ABBVIE INC. $571.20 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426070
Principal investigator 1 ABBVIE INC. $3,710.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426073
Principal investigator 1 ABBVIE INC. $172.20 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426077
Principal investigator 1 ABBVIE INC. $898.80 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426081
Principal investigator 1 ABBVIE INC. $2,590.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426085
Principal investigator 1 ABBVIE INC. $229.60 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426090
Principal investigator 1 ABBVIE INC. $114.80 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426094
Principal investigator 1 ABBVIE INC. $3,710.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426098
Principal investigator 1 ABBVIE INC. $2,590.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426102
Principal investigator 1 ABBVIE INC. $4,244.80 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426105
Principal investigator 1 ABBVIE INC. $5,531.40 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426109
Principal investigator 1 ABBVIE INC. $196.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426114
Principal investigator 1 ABBVIE INC. $4,244.80 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426119
Principal investigator 1 ABBVIE INC. $82.86 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426123
Principal investigator 1 ABBVIE INC. $172.20 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426127
Principal investigator 1 ABBVIE INC. $71.40 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426130
Principal investigator 1 ABBVIE INC. $91.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426134
Principal investigator 1 ABBVIE INC. $3,427.79 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426139
Principal investigator 1 ABBVIE INC. $308.38 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426143
Principal investigator 1 ABBVIE INC. $3,710.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426145
Principal investigator 1 ABBVIE INC. $2,590.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426150
Principal investigator 1 ABBVIE INC. $60.20 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426154
Principal investigator 1 ABBVIE INC. $112.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426158
Principal investigator 1 ABBVIE INC. $196.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426162
Principal investigator 1 ABBVIE INC. $3,710.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426168
Principal investigator 1 ABBVIE INC. $56.00 09/10/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202426172
Principal investigator 1 ABBVIE INC. $3,304.00 09/01/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425837
Principal investigator 1 ABBVIE INC. $3,809.40 09/01/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425846
Principal investigator 1 ABBVIE INC. $3,304.00 09/01/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425849
Principal investigator 1 Genentech, Inc. $5,600.00 08/04/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211552862
Principal investigator 1 ABBVIE INC. $3,304.00 07/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425755
Principal investigator 1 ABBVIE INC. $2,335.20 07/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425759
Principal investigator 1 ABBVIE INC. $3,304.00 07/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425763
Principal investigator 1 ABBVIE INC. $3,809.40 07/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425767
Principal investigator 1 ABBVIE INC. $2,699.20 07/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425771
Principal investigator 1 ABBVIE INC. $3,809.40 07/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425774
Principal investigator 1 ABBVIE INC. $3,528.00 07/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425777
Principal investigator 1 ABBVIE INC. $3,921.40 07/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425781
Principal investigator 1 ABBVIE INC. $3,304.00 07/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425785
Principal investigator 1 ABBVIE INC. $1,527.40 07/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425788
Principal investigator 1 ABBVIE INC. $2,020.20 07/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425792
Principal investigator 1 ABBVIE INC. $3,304.00 07/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425797
Recipient SERVIER PHARMACEUTICALS LLC $98.25 07/24/2025 Covered Recipient Physician A Phase 1b multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer No dispute reported 06/30/2026 1235964652
Recipient SERVIER PHARMACEUTICALS LLC $99.75 07/24/2025 Covered Recipient Physician A Phase 1b multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer No dispute reported 06/30/2026 1235964654
Principal investigator 1 Alnylam Pharmaceuticals Inc. $29,012.20 07/23/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination with Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma No dispute reported 06/30/2026 1215505505
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,332.80 07/18/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination with Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma No dispute reported 06/30/2026 1215505500
Principal investigator 1 ABBVIE INC. $3,809.40 06/27/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425729
Principal investigator 1 ABBVIE INC. $3,304.00 06/27/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425733
Principal investigator 1 ABBVIE INC. $1,667.40 05/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425602
Principal investigator 1 ABBVIE INC. $2,587.20 05/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425605
Principal investigator 1 ABBVIE INC. $5,007.80 05/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425609
Principal investigator 1 ABBVIE INC. $3,809.40 05/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425613
Principal investigator 1 ABBVIE INC. $1,867.60 05/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425617
Principal investigator 1 ABBVIE INC. $3,304.00 05/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425622
Principal investigator 1 ABBVIE INC. $4,950.40 05/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425627
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,055.00 05/01/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination with Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma No dispute reported 06/30/2026 1215505497
Principal investigator 1 ABBVIE INC. $3,921.40 04/30/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425552
Principal investigator 1 ABBVIE INC. $1,527.40 04/30/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425557
Principal investigator 1 ABBVIE INC. $2,335.20 04/30/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425561
Principal investigator 1 ABBVIE INC. $3,921.40 04/30/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425564
Principal investigator 1 ABBVIE INC. $2,020.20 04/30/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425568
Principal investigator 1 ABBVIE INC. $3,304.00 04/30/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425572
Principal investigator 1 ABBVIE INC. $2,335.20 04/30/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425574
Principal investigator 1 ABBVIE INC. $3,304.00 04/30/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425579
Principal investigator 1 ABBVIE INC. $3,304.00 04/30/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425583
Principal investigator 1 Genentech, Inc. $15,050.00 04/21/2025 Covered Recipient Teaching Hospital
Rainbow Babies & Childrens Hospita
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211552857
Principal investigator 1 ABBVIE INC. $3,528.00 03/31/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425494
Principal investigator 1 ABBVIE INC. $3,528.00 03/31/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425499
Principal investigator 1 ABBVIE INC. $2,699.20 03/31/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425503
Principal investigator 1 ABBVIE INC. $3,304.00 03/31/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425506
Principal investigator 1 ABBVIE INC. $2,020.20 03/31/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425510
Principal investigator 1 ABBVIE INC. $2,587.20 03/31/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425513
Principal investigator 1 ABBVIE INC. $3,304.00 03/31/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425518
Principal investigator 1 ABBVIE INC. $2,699.20 03/31/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425522
Principal investigator 1 ABBVIE INC. $1,667.40 03/31/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425526
Principal investigator 1 ABBVIE INC. $3,304.00 03/31/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425530
Recipient SERVIER PHARMACEUTICALS LLC $98.25 03/19/2025 Covered Recipient Physician A Phase 1b multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer No dispute reported 06/30/2026 1235964650
Principal investigator 1 ABBVIE INC. $4,191.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425176
Principal investigator 1 ABBVIE INC. $3,710.00 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425179
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425182
Principal investigator 1 ABBVIE INC. $614.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425186
Principal investigator 1 ABBVIE INC. $89.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425190
Principal investigator 1 ABBVIE INC. $4,191.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425194
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425198
Principal investigator 1 ABBVIE INC. $614.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425203
Principal investigator 1 ABBVIE INC. $3,710.00 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425206
Principal investigator 1 ABBVIE INC. $614.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425211
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425215
Principal investigator 1 ABBVIE INC. $89.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425218
Principal investigator 1 ABBVIE INC. $614.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425221
Principal investigator 1 ABBVIE INC. $2,590.00 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425226
Principal investigator 1 ABBVIE INC. $89.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425231
Principal investigator 1 ABBVIE INC. $2,590.00 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425235
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425239
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425242
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425246
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425250
Principal investigator 1 ABBVIE INC. $614.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425255
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425259
Principal investigator 1 ABBVIE INC. $190.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425263
Principal investigator 1 ABBVIE INC. $614.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425268
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425272
Principal investigator 1 ABBVIE INC. $210.00 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425277
Principal investigator 1 ABBVIE INC. $614.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425281
Principal investigator 1 ABBVIE INC. $3,710.00 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425285
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425289
Principal investigator 1 ABBVIE INC. $614.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425293
Principal investigator 1 ABBVIE INC. $89.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425297
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425301
Principal investigator 1 ABBVIE INC. $2,590.00 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425305
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425310
Principal investigator 1 ABBVIE INC. $3,030.93 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425314
Principal investigator 1 ABBVIE INC. $1,050.00 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425318
Principal investigator 1 ABBVIE INC. $3,710.00 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425322
Principal investigator 1 ABBVIE INC. $614.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425326
Principal investigator 1 ABBVIE INC. $614.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425329
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425333
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425337
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425341
Principal investigator 1 ABBVIE INC. $614.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425345
Principal investigator 1 ABBVIE INC. $3,710.00 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425348
Principal investigator 1 ABBVIE INC. $614.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425352
Principal investigator 1 ABBVIE INC. $190.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425355
Principal investigator 1 ABBVIE INC. $614.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425359
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425364
Principal investigator 1 ABBVIE INC. $614.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425368
Principal investigator 1 ABBVIE INC. $614.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425371
Principal investigator 1 ABBVIE INC. $614.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425376
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425381
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425385
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425389
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425393
Principal investigator 1 ABBVIE INC. $614.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425397
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425401
Principal investigator 1 ABBVIE INC. $7,000.00 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425405
Principal investigator 1 ABBVIE INC. $4,244.80 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425409
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425412
Principal investigator 1 ABBVIE INC. $4,950.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425417
Principal investigator 1 ABBVIE INC. $4,950.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425421
Principal investigator 1 ABBVIE INC. $190.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425425
Principal investigator 1 ABBVIE INC. $2,590.00 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425429
Principal investigator 1 ABBVIE INC. $210.00 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425433
Principal investigator 1 ABBVIE INC. $2,100.00 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425437
Principal investigator 1 ABBVIE INC. $2,590.00 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425441
Principal investigator 1 ABBVIE INC. $614.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425445
Principal investigator 1 ABBVIE INC. $614.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425448
Principal investigator 1 ABBVIE INC. $614.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425451
Principal investigator 1 ABBVIE INC. $614.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425455
Principal investigator 1 ABBVIE INC. $614.60 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425458
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425462
Principal investigator 1 ABBVIE INC. $57.40 03/05/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425467
Principal investigator 1 ABBVIE INC. $2,811.20 02/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425102
Principal investigator 1 ABBVIE INC. $5,007.80 02/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425106
Principal investigator 1 ABBVIE INC. $3,304.00 02/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425110
Principal investigator 1 ABBVIE INC. $3,304.00 02/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425114
Principal investigator 1 ABBVIE INC. $4,950.40 02/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425119
Principal investigator 1 ABBVIE INC. $2,587.20 02/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425123
Principal investigator 1 ABBVIE INC. $3,809.40 02/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425127
Principal investigator 1 ABBVIE INC. $3,304.00 02/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425130
Principal investigator 1 ABBVIE INC. $3,304.00 02/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425134
Principal investigator 1 ABBVIE INC. $3,304.00 02/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425137
Principal investigator 1 ABBVIE INC. $3,304.00 02/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425141
Principal investigator 1 ABBVIE INC. $2,811.20 02/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425147
Principal investigator 1 ABBVIE INC. $4,950.40 02/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425151
Principal investigator 1 ABBVIE INC. $3,304.00 02/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425155
Principal investigator 1 ABBVIE INC. $5,007.80 02/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425159
Principal investigator 1 ABBVIE INC. $1,667.40 02/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425163
Principal investigator 1 ABBVIE INC. $3,304.00 02/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425167
Principal investigator 1 ABBVIE INC. $3,304.00 02/28/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425171
Principal investigator 1 Alnylam Pharmaceuticals Inc. $36,750.00 02/05/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination with Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma No dispute reported 06/30/2026 1215505484
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,700.00 02/05/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination with Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma No dispute reported 06/30/2026 1215505488
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,500.00 02/05/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination with Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma No dispute reported 06/30/2026 1215505492
Principal investigator 1 ABBVIE INC. $3,304.00 01/29/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425058
Principal investigator 1 ABBVIE INC. $3,304.00 01/29/2025 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202425064